Online inquiry

IVTScrip™ mRNA-Anti-CD3E&MS4A1, CD20-TCB (2:1)(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5331MR)

This product GTTS-WQ5331MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CD3E&MS4A1 gene. The antibody can be applied in Lymphoma, B cell research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000733.4; NM_021950.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 931
UniProt ID P07766; P11836
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&MS4A1, CD20-TCB (2:1)(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ5331MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12910MR IVTScrip™ mRNA-Anti-FZD10, OTSA101-DTPA(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA OTSA101-DTPA
GTTS-WQ11389MR IVTScrip™ mRNA-Anti-PDGFRA, MEDI-575(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MEDI-575
GTTS-WQ7416MR IVTScrip™ mRNA-Anti-EGFR, GA201(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA GA201
GTTS-WQ7287MR IVTScrip™ mRNA-Anti-CSF1R, FPA-008(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA FPA-008
GTTS-WQ454MR IVTScrip™ mRNA-Anti-PDGFRA, 3G3(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 3G3
GTTS-WQ2219MR IVTScrip™ mRNA-Anti-VWF, aVWF81(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA aVWF81
GTTS-WQ7619MR IVTScrip™ mRNA-Anti-TNFRSF10B, GEN1029(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GEN1029
GTTS-WQ523MR IVTScrip™ mRNA-Anti-CD40, 4D11(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 4D11
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW